Streptomycin-starved Mycobacterium tuberculosis 18b, a drug discovery tool for latent tuberculosis

Antimicrobial Agents and Chemotherapy

Volumn 56, Issue 11, 2012, Pages 5782-5789

  Zhang, Ming ^a   Sala, Claudia ^a   Hartkoorn, Ruben C ^a   Dhar, Neeraj ^a   Mendoza Losana, Alfonso ^b   Cole, Stewart T ^a  

^a EPFL   (Switzerland)

^b GLAXOSMITHKLINE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; BEDAQUILINE; BENZOTHIADIAZINE DERIVATIVE; CLAVULANIC ACID; CLOFAZIMINE; CYCLOSERINE; ETHIONAMIDE; LINEZOLID; PYRAZINAMIDE; RESAZURIN; RIFAMPICIN; RIFAPENTINE; STREPTOMYCIN;

ANIMAL EXPERIMENT; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC SENSITIVITY; AREA UNDER THE CURVE; ARTICLE; BACTERIAL CELL WALL; BACTERIAL STRAIN; BACTERIUM CULTURE; BACTERIUM MUTANT; DRUG EFFICACY; DRUG EXPOSURE; DRUG SCREENING; IN VITRO STUDY; IN VIVO STUDY; LATENT VIRUS INFECTION; MOUSE; NONHUMAN; PRIORITY JOURNAL; STREPTOMYCIN STARVED MYCOBACTERIUM TUBERCULOSIS 18B; TUBERCULOSIS;

ACETAMIDES; AMINO ACID SEQUENCE; ANIMALS; ANTITUBERCULAR AGENTS; CLOFAZIMINE; DISEASE MODELS, ANIMAL; DRUG DISCOVERY; DRUGS, INVESTIGATIONAL; FEMALE; GENETIC ENGINEERING; LATENT TUBERCULOSIS; MICE; MICE, INBRED BALB C; MICROBIAL SENSITIVITY TESTS; MOLECULAR SEQUENCE DATA; MYCOBACTERIUM TUBERCULOSIS; OXAZINES; OXAZOLIDINONES; QUINOLINES; RIFAMPIN; STREPTOMYCIN; STRUCTURE-ACTIVITY RELATIONSHIP; XANTHENES;

EID: 84868007876     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01125-12     Document Type: Article

References (52)

1. Andries K, et al. 2005. A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis. Science 307:223-227.
2. Anoopkumar-Dukie S, et al. 2005. Resazurin assay of radiation response in cultured cells. Br. J. Radiol. 78:945-947.
3. Banerjee A, et al. 1994. inhA, a gene encoding a target for isoniazid and ethionamide in Mycobacterium tuberculosis. Science 263:227-230.
4. Barry CE, III, et al. 2009. The spectrum of latent tuberculosis: rethinking the biology and intervention strategies. Nat. Rev. Microbiol. 7:845-855.
5. Belanger AE, et al. 1996. The embAB genes of Mycobacterium avium encode an arabinosyl transferase involved in cell wall arabinan biosynthesis thatis the target for the antimycobacterial drug ethambutol. Proc. Natl. Acad. Sci. U. S. A. 93:11919-11924.
6. Betts JC, Lukey PT, Robb LC, McAdam RA, Duncan K. 2002. Evaluation of a nutrient starvation model of Mycobacterium tuberculosis persistence by gene and protein expression profiling. Mol. Microbiol. 43:717-731.
7. Blumberg HM, et al. 2003. American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis. Am. J. Respir. Crit. Care Med. 167:603-662.
8. Boshoff HI, and Barry CE, III. 2005. Tuberculosis - metabolism and respiration in the absence of growth. Nat. Rev. Microbiol. 3:70-80.
9. Chambers HF, Kocagoz T, Sipit T, Turner J, Hopewell PC. 1998. Activity of amoxicillin/clavulanate in patients with tuberculosis. Clin. Infect. Dis. 26:874-877.
10. Chan J, Flynn J. 2004. The immunological aspects of latency in tuberculosis. Clin. Immunol. 110:2-12.
11. Cholo MC, Steel HC, Fourie PB, Germishuizen WA, Anderson R. 2012. Clofazimine: current status and future prospects. J. Antimicrob. Chemother. 67:290-298.
12. Cole ST, Riccardi G. 2011. New tuberculosis drugs on the horizon. Curr. Opin. Microbiol. 14:570-576.
13. Corbett EL, et al. 2003. The growing burden of tuberculosis: global trends and interactions with the HIV epidemic. Arch. Intern. Med. 163:1009-1021.
14. De Bruyn EE, Steel HC, Van Rensburg EJ, Anderson R. 1996. The riminophenazines, clofazimine and B669, inhibit potassium transport in gram-positive bacteria by a lysophospholipid-dependent mechanism. J. Antimicrob. Chemother. 38:349-362.
15. Dooley KE, Chaisson RE. 2009. Tuberculosis and diabetes mellitus: convergence of two epidemics. Lancet Infect. Dis. 9:737-746.
16. Dye C. 2006. Global epidemiology of tuberculosis. Lancet 367:938-940.
17. Edwards JR. 1995. Meropenem: a microbiological overview. J. Antimicrob. Chemother. 36(Suppl. A):1-17.
18. Gandhi NR, et al. 2006. Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa. Lancet 368:1575-1580.
19. Hartkoorn RC, et al. 17 September 2012. Towards a new tuberculosis drug: pyridomycin-nature's isoniazid. EMBO Mol. Med. [Epub ahead of print.] doi:10.1002/emmm.201201689.
20. Hashimoto T. 1955. Experimental studies on the mechanism of infection and immunity in tuberculosis from the analytical standpoint of streptomycin- dependent tubercle bacilli. 1. Isolation and biological characteristics of a streptomycin-dependent mutant, and effect of streptomycin administration on its pathogenicity in guinea-pigs. Kekkaku 30:4-8. (In Japanese with English summary.)
21. Hugonnet JE, Tremblay LW, Boshoff HI, Barry CE, III, Blanchard JS. 2009. Meropenem-clavulanate is effective against extensively drugresistant Mycobacterium tuberculosis. Science 323:1215-1218.
22. Ibrahim M, et al. 2007. Synergistic activity of R207910 combined with pyrazinamide against murine tuberculosis. Antimicrob. Agents Chemother. 51:1011-1015.
23. Lounis N, et al. 2006. Combinations of R207910 with drugs used to treat multidrug-resistant tuberculosis have the potential to shorten treatment duration. Antimicrob. Agents Chemother. 50:3543-3547.
24. Maeda K, Kosaka H, Okami Y, Umezawa H. 1953. A new antibiotic, pyridomycin. J. Antibiotics 6:140.
25. Makarov V, et al. 2009. Benzothiazinones kill Mycobacterium tuberculosis by blocking arabinan synthesis. Science 324:801-804.
26. McCune RM, Jr, McDermott W, Tompsett R. 1956. The fate of Myco-bacterium tuberculosis in mouse tissues as determined by the microbial enumeration technique. II. The conversion of tuberculous infection to the latent state by the administration of pyrazinamide and a companion drug. J. Exp. Med. 104:763-802.
27. McCune RM, Jr, Tompsett R. 1956. Fate of Mycobacterium tuberculosis in mouse tissuesasdeterminedbythe microbial enumeration technique. I. The persistence of drug-susceptible tubercle bacilli in the tissues despite prolonged antimicrobial therapy. J. Exp. Med. 104:737-762.
28. Mukherjee JS, et al. 2004. Programmes and principles in treatment of multidrug-resistant tuberculosis. Lancet 363:474-481.
29. Oliva B, O'Neill AJ, Miller K, Stubbings W, Chopra I. 2004. Antistaphylococcal activity and mode of action of clofazimine. J. Antimicrob. Chemother. 53:435-440.
30. Phetsuksiri B, et al. 2003. Unique mechanism of action of the thiourea drug isoxyl on Mycobacterium tuberculosis. J. Biol. Chem. 278:53123-53130.
31. Rao SP, Alonso S, Rand L, Dick T, Pethe K. 2008. The protonmotive force is required for maintaining ATP homeostasis and viability of hypoxic, nonreplicating Mycobacterium tuberculosis. Proc. Natl. Acad. Sci. U. S. A. 105:11945-11950.
32. Reddy VM, Nadadhur G, Daneluzzi D, O'Sullivan JF, Gangadharam PR. 1996. Antituberculosis activities of clofazimine and its new analogs B4154 and B4157. Antimicrob. Agents Chemother. 40:633-636.
33. Rosenthal IM, Zhang M, Almeida D, Grosset JH, Nuermberger EL. 2008. Isoniazid or moxifloxacin in rifapentine-based regimens for experimental tuberculosis? Am. J. Respir. Crit. Care Med. 178:989-993.
34. Rosenthal IM, et al. 2007. Daily dosing of rifapentine cures tuberculosis in three months or less in the murine model. PLoS Med. 4:e344. doi: 10.1371/journal.pmed.0040344.
35. Sala C, et al. 2010. Simple model for testing drugs against nonreplicating Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 54:4150-4158.
36. Shen GH, et al. 2010. High efficacy of clofazimine and its synergistic effect with amikacin against rapidly growing mycobacteria. Int. J. Antimicrob. Agents 35:400-404.
37. Shi W, et al. 2011. Pyrazinamide inhibits trans-translation in Mycobacterium tuberculosis. Science 333:1630-1632.
38. Singh R, et al. 2008. PA-824 kills nonreplicating Mycobacterium tuberculosis by intracellular NO release. Science 322:1392-1395.
39. Slayden RA, et al. 1996. Antimycobacterial action of thiolactomycin: an inhibitor of fatty acid and mycolic acid synthesis. Antimicrob. Agents Chemother. 40:2813-2819.
40. Steel HC, Matlola NM, Anderson R. 1999. Inhibition of potassium transport and growth of mycobacteria exposed to clofazimine and B669 is associated with a calcium-independent increase in microbial phospholipase A2 activity. J. Antimicrob. Chemother. 44:209-216.
41. Sterling TR, et al. 2011. Three months of rifapentine and isoniazid for latent tuberculosis infection. N. Engl. J. Med. 365:2155-2166.
42. Tahlan K, et al. 2012. SQ109 targets MmpL3, a membrane transporter of trehalose monomycolate involved in mycolic acid donationtothe cell wall core of Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 56: 1797-1809.
43. Vilcheze C, et al. 2006. Transfer of a point mutation in Mycobacterium tuberculosis inhA resolves the target of isoniazid. Nat. Med. 12:1027-1029.
44. Villemagne B, et al. 2012. Tuberculosis: the drug development pipeline at a glance. Eur. J. Med. Chem. 51:1-16.
45. Wayne LG, Hayes LG. 1996. An in vitro model for sequential study of shiftdown of Mycobacterium tuberculosis through two stages of nonreplicating persistence. Infect. Immun. 64:2062-2069.
46. Wayne LG, Sohaskey CD. 2001. Nonreplicating persistence of Mycobacterium tuberculosis. Annu. Rev. Microbiol. 55:139-163.
47. Williams K, et al. 2012. Sterilizing activity of novel combinations lacking first- and second-line drugs in a murine model of tuberculosis. Antimicrob. Agents Chemother. 56:3114-3120.
48. Xie Z, Siddiqi N, Rubin EJ. 2005. Differential antibiotic susceptibilities of starved Mycobacterium tuberculosis isolates. Antimicrob. Agents Chemother. 49:4778-4780.
49. Yano T, et al. 2011. Reduction of clofazimine by mycobacterial type 2 NADH: quinone oxidoreductase: a pathway for the generation of bactericidal levels of reactive oxygen species. J. Biol. Chem. 286:10276-10287.
50. Zhang M, et al. 2011. Treatment of tuberculosis with rifamycin-containing regimens in immune-deficient mice. Am. J. Respir. Crit. Care Med. 183:1254-1261.
51. Zhang T, Zhang M, Rosenthal IM, Grosset JH, Nuermberger EL. 2009. Short-course therapy with daily rifapentine in a murine model of latent tuberculosis infection. Am. J. Respir. Crit. Care Med. 180:1151-1157.
52. Zhang Y. 2005. The magic bullets and tuberculosis drug targets. Annu. Rev. Pharmacol. Toxicol. 45:529-564.